Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia

Table 1

Clinical studies, types of renal disease, and treatment in Waldenström’s macroglobulinemia.

Study	Number of patients	Pathology seen	Treatment
Morel-Maroger et al. [2]	16 patients	3 amyloidosis; 6 nonamyloid glomerular disease (3 cryoglobulinemia); 7 had no detectable lesions	Not available
Higgins et al. [1]	44 patients	17 amyloidosis; 9 nonamyloid glomerular disease; 7 tubulointerstitial nephritis; 9 non-monoclonal gammopathy-related glomerular disease (1FSGS)	Amyloid glomerulopathy: Rituximab R; Ituximab; Chemotherapy; Bortezomib; Nonamyloid glomerulopathy: Steroid; Rituximab; Rituxima; Bendamustine; Bortezomib; Chemotherapy
Vos et al. [3]	44 patients	Amyloidosis 11; Cryoglobulinemia 10; Light-chain deposition disease 4; Cast nephropathy 4; TMA 3; Minimal change disease 2; Membranous nephropathy 1; LPL infiltration 8; Light-chain tubulopathy 1	Proteosome inhibitor + rituximab; Alkylator + rituximab; Nucleoside analogue + rituximab; Bendamustine; Single-agent rituximab

LPL: lymphoplasmacytic lymphoma infiltration; TMA: thrombotic microangiopathy.